NAFDAC Issues Alert on Counterfeit Augmentin Tablets Circulating in Nigeria

The National Agency for Food and Drug Administration and Control (NAFDAC) has warned healthcare providers, pharmacies, and the general public about the circulation of counterfeit Augmentin 625mg Tablets bearing Batch No. AC3N.

In Public Alert No. 024/2026, NAFDAC stated that it received information from the Marketing Authorisation Holder for GlaxoSmithKline (GSK) products in Nigeria following multiple complaints about suspected falsified versions of the popular antibiotic.

GSK confirmed the products as counterfeit after reviewing evidence, including photographs and social media videos.

Key Details of the Counterfeit Product
• Product Name: Augmentin 625mg Tablets (amoxicillin/clavulanic acid)
• Pack Size: 2 x 7 tablets
• Batch Number: AC3N
• Genuine Manufacturer: GlaxoSmithKline (GSK), Worthing Site, United Kingdom
Counterfeit indicators (per GSK investigation):
• The suspect samples show manufacturing date September 2025 and expiry September 2028.
• Authentic Batch AC3N was manufactured on 23 August 2023 and packed on 19–20 September 2023 at GSK’s UK facility. No batch with this number was produced in 2025.
• Packaging discrepancies, including textual errors and poor fin seal quality.

Augmentin is a widely used antibiotic for bacterial infections. Counterfeit versions may contain incorrect amounts of active ingredients, no active ingredients, or harmful substances.

NAFDAC has directed zonal directors and state coordinators to intensify surveillance and remove the counterfeit products from circulation. The agency reiterated its commitment to protecting public health through ongoing monitoring of the medicine supply chain.

This alert comes amid broader efforts by NAFDAC to combat falsified medicines in Nigeria. No confirmed cases of harm from this specific batch have been detailed in the alert, but officials stress vigilance due to the potential dangers.